Aspirin and reproductive outcomes.

Area of Science:

• Reproductive Medicine
• Maternal-Fetal Medicine
• Pharmacology

Background:

• Aspirin's potential role in preventing preeclampsia was hypothesized in the late 1980s/early 1990s.
• It's used to improve outcomes in antiphospholipid antibody syndrome and in vitro fertilization.
• Aspirin's cyclooxygenase inhibition has theoretical positive and negative reproductive effects.

Purpose of the Study:

• To evaluate the efficacy and safety of aspirin in managing pregnancy complications.
• To assess aspirin's role in preventing preeclampsia and improving outcomes in specific high-risk groups.
• To review the balance of benefits and risks of aspirin use during pregnancy.

Main Methods:

• Numerous clinical trials have investigated aspirin's effects on pregnancy outcomes.
• Studies assessed aspirin's impact on preeclampsia, antiphospholipid syndrome, and IVF success.
• Risk-benefit analyses considered maternal and fetal safety profiles.

Main Results:

• Trials demonstrated limited but positive results for aspirin in preeclampsia prevention.
• Aspirin use showed mixed outcomes in antiphospholipid syndrome and IVF.
• Potential risks include maternal/fetal bleeding and vascular disruptions (e.g., gastroschisis).

Conclusions:

• Low-dose aspirin is increasingly used to reduce risks of maternal thrombosis, miscarriage, and poor pregnancy outcomes.
• Evidence for aspirin's benefit in antiphospholipid syndrome remains inconclusive.
• Large trials support low-dose aspirin's relative safety and generally positive reproductive effects.